Last reviewed · How we verify
Oxygen 80 %
At a glance
| Generic name | Oxygen 80 % |
|---|---|
| Sponsor | Medical University of Vienna |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Auto-immunity and Pulmonary Arterial Hypertension (NA)
- THRIVE in Sedated Gastrointestinal Endoscopy
- Combination Therapy to Improve SCI Recovery. (NA)
- Low Oxygen Therapy to Enhance Walking Recovery After SCI. (NA)
- A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs (PHASE3)
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2) (PHASE2)
- Acute Effects of High-intensity Interval Aerobic and Functional Training at Different Intensities (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |